(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 4.33% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.74%.
Johnson & Johnson's revenue in 2025 is $92,149,000,000.On average, 27 Wall Street analysts forecast JNJ's revenue for 2025 to be $228,128,925,323,074, with the lowest JNJ revenue forecast at $220,570,966,588,100, and the highest JNJ revenue forecast at $237,920,300,617,602. On average, 27 Wall Street analysts forecast JNJ's revenue for 2026 to be $240,165,763,652,666, with the lowest JNJ revenue forecast at $231,909,109,338,112, and the highest JNJ revenue forecast at $252,055,634,981,036.
In 2027, JNJ is forecast to generate $252,077,318,636,954 in revenue, with the lowest revenue forecast at $238,421,433,998,818 and the highest revenue forecast at $266,015,090,802,024.